Meyer Andrew Hollman, an insider at Janux Therapeutics Inc (JANX), purchased 88,307 shares of the company's stock at a price of $10.59 per share on November 13, 2025. The total transaction value amounted to $935,000. Following this acquisition, Hollman now holds 88,307 shares of Janux Therapeutics.
Janux Therapeutics operates as a preclinical stage biopharmaceutical company focused on developing therapeutics based on its Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California, and has a market capitalization of $1.6 billion. Its clinical candidates include JANX007 and JANX008, targeting prostate cancer and multiple solid tumors, respectively.
Insider transactions are reported to the SEC, providing insight into the actions of company executives and board members. While insider buying can indicate confidence in a company's prospects, it is important for investors to consider these transactions in conjunction with other fundamental and technical factors.
Janux Therapeutics is expected to report earnings on May 5, 2026, with an estimated EPS of -$0.74 and revenue of $224,400.